{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/heart-failure-chronic/prescribing-information/managing-aiiras/","result":{"pageContext":{"chapter":{"id":"8fd96acc-3fa6-528b-9351-49db836228b1","slug":"managing-aiiras","fullItemName":"Managing AIIRAs","depth":2,"htmlHeader":"<!-- begin field c9e5506b-e509-4cb7-bc85-2a740b21b183 --><h2>Angiotensin-II receptor antagonists</h2><!-- end field c9e5506b-e509-4cb7-bc85-2a740b21b183 -->","summary":"","htmlStringContent":"<!-- begin item 2502d4a7-47fc-436d-b52b-397f8a3503a7 --><!-- end item 2502d4a7-47fc-436d-b52b-397f8a3503a7 -->","topic":{"id":"3a35207f-30ea-5eca-bfcf-dff091a73359","topicId":"fdc42e20-2c4b-45ed-9093-6c2d4bde6e4d","topicName":"Heart failure - chronic","slug":"heart-failure-chronic","lastRevised":"Last revised in January 2017","chapters":[{"id":"77c928c1-46d0-58c1-ba79-6015f89bc48a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f0aa9151-9d10-566e-85ec-6ccefed25f20","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c036596d-f29d-5486-822a-b46af76451d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"fd5e8a95-3e97-5ec2-98ae-5a10c2373213","slug":"changes","fullItemName":"Changes"},{"id":"4c4375f1-a348-5b99-b895-f04a15c64791","slug":"update","fullItemName":"Update"}]},{"id":"7472c037-35d4-5fd2-bba6-dfd891ade816","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cde936d1-3945-5bc6-8c22-9106d78cf77c","slug":"goals","fullItemName":"Goals"},{"id":"bfa0b8d3-fac0-500e-a762-f719dc619f1b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5d2cf55e-1ae2-5000-9c94-e9c86d26a824","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c8203a8a-fc22-5378-b33b-34ddf818dea5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4b5e4f72-1a3e-531c-be82-a1919603c934","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c206f1b2-7616-587d-b3bf-b65ba5b5adb4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ab1d2b81-1f2b-55e5-abf0-c14e4ae4a78d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"cb83ac3c-e97e-5cab-acca-5abebc7bd6b1","slug":"definition","fullItemName":"Definition"},{"id":"66c995b7-504c-5510-9e77-1a9b27ee7dca","slug":"causes","fullItemName":"Causes"},{"id":"88dbdf7b-53b7-5952-97b9-2312c0a2ce63","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a0b16521-d808-5dfd-89dc-64fc6ae7f6ce","slug":"prognosis","fullItemName":"Prognosis"},{"id":"262fb896-526d-594f-8142-98c291781249","slug":"complications","fullItemName":"Complications"}]},{"id":"72804751-fb0c-5a96-85b5-982feb950f16","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8b798e41-3fbe-5027-9365-da41e1c98e93","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"e6498250-f313-5ea2-a1e8-2d0342823c39","slug":"how-to-manage-suspected","fullItemName":"How to manage suspected"},{"id":"74e553b4-7cb8-52a6-a573-8715f63a2ba8","slug":"how-to-assess","fullItemName":"How to assess"},{"id":"53bf7ae0-a1d0-5fae-9d3b-57cbc6f03bb8","slug":"what-else-could-it-be","fullItemName":"What else could it be"}]},{"id":"38c5edc8-6b4a-5e71-bb70-cf0a09389ae0","fullItemName":"Management","slug":"management","subChapters":[{"id":"97a0eca4-a290-588b-a16a-bc95b93cd893","slug":"confirmed-heart-failure-with-reduced-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with reduced ejection fraction"},{"id":"34ff8094-815a-55b7-9edd-49f3ac636471","slug":"confirmed-heart-failure-with-preserved-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with preserved ejection fraction"},{"id":"28fde475-ef24-59d3-9171-a8d59a3fb149","slug":"end-stage-heart-failure","fullItemName":"Scenario: End-stage heart failure"},{"id":"c587255a-a47e-57a1-bc4d-967753c38d11","slug":"information-advice-follow-up-referral","fullItemName":"Scenario: Information and advice, follow-up, and referral"}]},{"id":"e82d6013-cb43-59d5-9e2e-0af05276fb9d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8fd96acc-3fa6-528b-9351-49db836228b1","slug":"managing-aiiras","fullItemName":"Managing AIIRAs"},{"id":"06c9d276-e5ea-5a0b-9ff4-343f10034763","slug":"managing-ace-inhibitors","fullItemName":"Managing ACE-inhibitors"},{"id":"df53e9a8-07f8-5d37-94cf-78e99d4c8216","slug":"managing-beta-blockers","fullItemName":"Managing beta-blockers"},{"id":"faad170c-d1ee-59ad-9847-f7afdda6d9b9","slug":"managing-diuretics","fullItemName":"Managing diuretics"},{"id":"a3ea6beb-7ee3-586c-9985-47c20d804195","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"7b9c5d56-39f1-53df-b1f9-2dcc5bbb498a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"df3b6e0c-ca5a-59eb-93e6-4b4370389ed2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7a756ff1-7152-5bdd-92ca-7f9e67351dd9","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f5e1707e-f2a9-54e0-92fa-71beb41e38af","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"691681cc-720f-5242-9fb3-3040860027e7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7f39ec24-cb87-5fba-ae6b-6fb2d9538859","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4afe2b30-f837-53a3-88df-7b1913a54081","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d4dace55-ef1c-5675-bdbe-180512d549fa","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e82d6013-cb43-59d5-9e2e-0af05276fb9d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"f0418250-54e0-5598-992b-1096266b463f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 065eccc5-9775-4e1d-9808-fd897d769181 --><h3>Adverse effects of AIIRAs</h3><!-- end field 065eccc5-9775-4e1d-9808-fd897d769181 -->","summary":"","htmlStringContent":"<!-- begin item 8146bcb7-73e0-4b34-bcfc-2167facf7bff --><!-- begin field 36e32b37-4729-4dec-8779-9cacf616b77d --><ul><li><strong>Adverse effects of angiotensin-II receptor antagonists (AIIRAs) include:</strong><ul><li><strong>Hypotension</strong> — which may cause dizziness and syncope. This occurs more commonly in people with hypovolaemia or hyponatraemia.</li><li><strong>Deterioration in renal function</strong> — monitor renal function after starting an AIIRA, after each dose increase, and every 3-6 months.</li><li><strong>Hyperkalaemia</strong> — monitor serum electrolytes after starting an AIIRA, after each dose increase, and every 3-6 months.</li></ul></li><li><strong>Less common adverse effects include:</strong><ul><li>Angio-oedema.</li><li>Malaise, vertigo, headaches, and sleep disorders.</li><li>Gastrointestinal disturbances, nausea, elevated liver function tests, hepatitis, pancreatitis.</li><li>Blood disorders — anaemia, thrombocytopaenia.</li><li>Hyponatraemia, hypoglycaemia.</li><li>Rash, urticaria, pruritus, vasculitis, photosensitivity.</li><li>Back pain, arthralgia, paraesthesia, rhabdomyolysis.</li><li>Depression.</li><li>Erectile dysfunction.</li><li>Angina, palpitations, atrial fibrillation, stroke, oedema, dyspnoea.</li><li>Cough (rare).</li><li>Diarrhoea has been noted as an adverse effect of candesartan. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field 36e32b37-4729-4dec-8779-9cacf616b77d --><!-- end item 8146bcb7-73e0-4b34-bcfc-2167facf7bff -->","subChapters":[]},{"id":"29e2dc5f-ae89-5170-a3ce-36f1ceda99b1","slug":"key-drug-interactions","fullItemName":"Key drug interactions","depth":3,"htmlHeader":"<!-- begin field de43a37e-6199-4fc8-a9bc-aaae2042fa0e --><h3>Key drug interactions with AIIRAs</h3><!-- end field de43a37e-6199-4fc8-a9bc-aaae2042fa0e -->","summary":"","htmlStringContent":"<!-- begin item b7359a1b-1b42-4f4d-adc6-534f62455ac9 --><!-- begin field 199971df-dd5e-4891-88cf-d1b1ac8b4ef4 --><p><strong>Important drug interactions of angiotensin-II receptor antagonists (AIIRAs) include:</strong></p><ul><li><strong>Aliskiren</strong> (a direct renin inhibitor) — combination therapy is not recommended. The combination of AIIRAs with aliskiren is contraindicated in people with diabetes mellitus or if the estmated glomerular filtration rate (eGFR) is less than 60 mL/min/1.73 m<sup>2</sup>.</li><li><strong>Angiotensin-converting enzyme (ACE) inhibitors</strong> — concomitant prescribing is not recommended (unless under specialist supervision).</li><li><strong>Antibiotics</strong> — risk of hyperkalaemia with trimethoprim.</li><li><strong>Antidiabetic agents</strong> — monitor glycaemic control closely during the first month of treatment due to increased blood glucose lowering effect with risk of hypoglycaemia. People with chronic kidney disease (CKD) are particularly at risk.</li><li><strong>Antihypertensives</strong> — monitor blood pressure due to increased hypotensive effect.</li><li><strong>Antipsychotics</strong> — monitor blood pressure due to increased hypotensive effect.</li><li><strong>Baclofen</strong> — monitor blood pressure due to increased hypotensive effect.</li><li><strong>Contraceptives and hormone replacement therapy</strong> containing drospirenone — potassium concentration should be measured during the first month of treatment.</li><li><strong>Diuretics</strong> — people already prescribed a diuretic may experience hypotension which may be profound. For people on 80 mg of furosemide or equivalent or above, consider discontinuing the diuretic for at least 24 hours prior to initiation of treatment or seeking specialist advice. For a person on a diuretic starting an ACE-inhibitor, the first dose of ACE-inhibitor can be taken at bedtime.</li><li><strong>Heparin</strong> (including low-molecular weight heparin) — monitor potassium regularly (every 4 days) in particular in people at increased risk such as those with chronic kidney disease or diabetes mellitus.</li><li><strong>Levodopa</strong> — monitor blood pressure due to increased hypotensive effect.</li><li><strong>Lithium</strong> — concurrent treatment is not recommended, but if considered essential careful monitoring of lithium levels is required.</li><li><strong>Nitrates</strong> — monitor blood pressure due to increased hypotensive effect.</li><li><strong>Nonsteroidal anti-inflammatory drugs</strong> — concurrent treatment not recommended due to the risk of deterioration in renal function which can rarely cause acute kidney injury particularly in the elderly, people who are dehydrated, or with CKD.</li><li><strong>Potassium supplements/potassium salts</strong> — avoid or monitor serum potassium due to increased risk of hyperkalaemia. People with CKD or diabetes mellitus are particularly at risk of hyperkalaemia.</li><li><strong>Potassium-sparing diuretics</strong> — risk of hyperkalaemia particularly in the presence of other risk factors such as advanced age, diabetes mellitus, doses of spironolactone greater than 25 mg daily and CKD. Close monitoring of potassium is needed and the presence of a loop diuretic may not prevent hyperkalaemia. It has been suggested that spironolactone should not be given with AIIRAs in people with an eGFR under 30 mL/min/1.73 m<sup>2</sup>.</li><li><strong>Tricyclic antidepressants</strong> — monitor blood pressure due to increased hypotensive effect.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field 199971df-dd5e-4891-88cf-d1b1ac8b4ef4 --><!-- end item b7359a1b-1b42-4f4d-adc6-534f62455ac9 -->","subChapters":[]},{"id":"cf5bcec6-3ab9-5f1f-94ff-16703ae6c5a1","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 84402a15-882e-4046-9180-14310c77d289 --><h3>AIIRAs in pregnancy and breastfeeding</h3><!-- end field 84402a15-882e-4046-9180-14310c77d289 -->","summary":"","htmlStringContent":"<!-- begin item e5b6e4cb-ec8b-4b32-b17f-55f6a4617853 --><!-- begin field 66ae4965-26f9-4b70-b262-448022e3d710 --><p><strong>Pregnancy</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">UKTIS, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015c</a>]</p><ul><li>There are limited data regarding exposure to AIIRAs in pregnancy but there are case reports of congenital malformations, fetal renal damage, oligohydramnios, skull defects, and death in infants exposed to AIIRAs in utero.</li><li>AIIRAs are not recommended during the first trimester of pregnancy.</li><li>AIIRAs are contraindicated during the second and third trimester of pregnancy.</li></ul><p><strong>Breastfeeding</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">MHRA, 2009</a>]</p><ul><li>AIIRAs are not recommended for use by women who are breastfeeding.</li></ul><!-- end field 66ae4965-26f9-4b70-b262-448022e3d710 --><!-- end item e5b6e4cb-ec8b-4b32-b17f-55f6a4617853 -->","subChapters":[]},{"id":"d90ec840-65ea-5023-93c8-16abf6995c12","slug":"dose-titration-monitoring","fullItemName":"Dose, titration, and monitoring","depth":3,"htmlHeader":"<!-- begin field d30cc881-ded6-4e4d-9d0d-2cfda9c65e5c --><h3>Dose, titration, and monitoring of AIIRAs</h3><!-- end field d30cc881-ded6-4e4d-9d0d-2cfda9c65e5c -->","summary":"","htmlStringContent":"<!-- begin item a8bbdc9d-22e7-4f7f-95f5-5bc06ff06f2e --><!-- begin field 1e2d3d37-942a-4e02-bd59-47bbccb9bb09 --><ul><li><strong>Seek specialist advice before commencing treatment if the person is using high doses of a loop diuretic</strong> (equivalent to 80 mg furosemide daily or more).</li><li><strong>Measure renal function, serum electrolytes, and blood pressure before prescribing an angiotensin-II receptor antagonist (AIIRA), then start a low dose(starting doses are given in Table 2).</strong><ul><li>If the person has chronic kidney disease (CKD) and a serum potassium greater than 5 mmol/L do not start treatment with an AIIRA.</li><li>Advise the person to be aware of the possibility of first-dose hypotension particularly if a diuretic is concurrently prescribed. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-aiiras/#key-drug-interactions\">Drug interactions</a>.</li></ul></li><li><strong>Recheck renal function, serum electrolytes, and blood pressure 1–2 weeks after starting treatment.</strong><ul><li>Earlier monitoring (after 5–7 days) may be required for people:<ul><li>With existing CKD stage 3 or higher</li><li>Aged 60 years or over.</li><li>With relevant comorbidities such as diabetes mellitus or peripheral arterial disease.</li><li>Taking a combination of an a AIIRA plus a diuretic or an aldosterone antagonist.</li></ul></li><li>Some increase in serum creatinine and potassium levels is expected after starting or increasing the dose of an AIIRA. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-aiiras/#managing-abnormal-results\">Managing abnormal results</a>.</li></ul></li><li><strong>Titrate the dose upwards at short intervals</strong> (for example every 2 weeks) until the target dose or the highest tolerated dose is reached.<ul><li>After each upward titration, monitor the person's renal function and blood pressure. Do not increase the dose further if there is worsening renal function or hyperkalaemia.</li><li>For interpretation of monitoring, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-aiiras/#managing-abnormal-results\">Managing abnormal results</a>.</li></ul></li><li><strong>Maintain the AIIRA at the target dose (or highest tolerated dose) indefinitely unless adverse effects occur.</strong></li><li><strong>Once treatment is stable, measure renal function and serum electrolytes at least every monthly for 3 months and then at least every six months and at any time if the person becomes acutely unwell. </strong><ul><li>More frequent monitoring may be required if clincially appropriate, when there are concerns regarding the person's clinical condition, concomitant drugs, or comorbidities.</li></ul></li><li><strong>Advise the person that if they develop diarrhoea and vomiting while taking an AIIRA,</strong> they should maintain their fluid intake and stop the AIIRA for 1–2 days until they recover.<ul><li>Stopping treatment for a short time is thought to avoid dehydration, hypotension, and acute kidney injury, and should not cause a sudden deterioration in heart failure.</li><li>If symptoms persist beyond 2 days they should see a GP and have their renal function checked.</li><li>For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/management/information-advice-follow-up-referral/#information-advice\">Self-care advice</a>.</li></ul></li></ul><p><strong>Table 2.</strong> Doses of recommended AIIRAs for heart failure.</p><table data-table-id=\"e2c8a2b3-a374-42f0-b37d-acce014f1120\"><thead><tr><th colspan=\"1\" scope=\"col\">AIIRA</th><th colspan=\"1\" scope=\"col\">Initial dose</th><th colspan=\"1\" scope=\"col\">Target dose</th></tr></thead><tbody><tr><td colspan=\"1\">Candesartan</td><td colspan=\"1\">4 mg once a day</td><td colspan=\"1\">32 mg once a day</td></tr><tr><td colspan=\"1\">Losartan</td><td colspan=\"1\">12.5 mg once a day</td><td colspan=\"1\">150 mg once a day</td></tr><tr><td colspan=\"1\">Valsartan</td><td colspan=\"1\">40 mg twice a day</td><td colspan=\"1\">160 mg twice a day</td></tr><tr><td colspan=\"3\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</td></tr></tbody></table><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Smellie et al, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">London and South East Medicines Information Service et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">National Clinical Guideline Centre for Acute and Chronic Conditions, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">McKelvie et al, 2013</a>] <span class=\"Citation\">[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">National Clinical Guidelines Centre, 2014</a>]</span></p><!-- end field 1e2d3d37-942a-4e02-bd59-47bbccb9bb09 --><!-- end item a8bbdc9d-22e7-4f7f-95f5-5bc06ff06f2e -->","subChapters":[]},{"id":"7b0dca34-b1ff-53c3-a6fe-015dbbaa7702","slug":"managing-abnormal-results","fullItemName":"Managing abnormal results","depth":3,"htmlHeader":"<!-- begin field 0685795b-58a4-4c70-a65c-3641e0d96f8a --><h3>Managing abnormal results with AIIRAs</h3><!-- end field 0685795b-58a4-4c70-a65c-3641e0d96f8a -->","summary":"","htmlStringContent":"<!-- begin item 15bfad7f-afbf-4e13-89ff-63c3858eb5cf --><!-- begin field 094780db-e6ba-4b81-a70b-d2cbf5dccf87 --><ul><li><strong>Some increase in creatinine and potassium levels is expected after starting or increasing the dose of an angiotensin-II receptor antagonist (AIIRA).</strong></li><li><strong>Managing creatinine and estimated glomerular filtration rate (eGFR)</strong><ul><li>If the serum creatinine level increases by more than 20% or the eGFR falls more than 15%, re-measure renal function within 2 weeks.</li><li>An increase of the serum creatinine level of less than 30% does not require further action.</li><li>An increase of the serum creatinine level of 30-50% (or to over 200 micromol/L) or eGFR less than 30 mL/min/1.73 m<sup>2</sup> should prompt clinical review of volume status and temporary dose reduction or withdrawal of the diuretic or AIIRA.</li><li>An increase of the serum creatinine level of more than 50% or to a level so greater than 256 micromol/L (eGFR approximately 20-25 mL/min/1.73 m<sup>2</sup>) should prompt dose reduction or withdrawal of diuretic and/or stopping the AIIRA and consideration of specialist referral.</li><li>An increase in the serum creatinine level of more than 100% or to greater than 310 micromol/L or eGFR less than 20 mL/min/1.73 m<sup>2</sup>, stop the AIIRA and seek specialist advice.</li><li>If the eGFR decreases by 25% or more, or the serum creatinine level increases by 30% or more, investigate other causes of deteriorating renal function, such as volume depletion. Stop or reduce the dose of the following drugs (where appropriate) if the person is taking them:<ul><li>Nephrotoxic drugs (such as nonsteroidal anti-inflammatory drugs).</li><li>Vasodilators (such as calcium-channel blockers, nitrates).</li><li>Potassium supplements or potassium-sparing diuretics.</li><li>Diuretics (consider dose reduction if the person is hypovolaemic).</li></ul></li><li>If the decrease in eGFR or the increase in serum creatinine level persists despite these measures:<ul><li>Stop the AIIRA, or reduce the dose to a previously tolerated lower dose and recheck levels in 5–7 days.</li></ul></li><li>If there is a significant decline in the eGFR consider the possibility of renal artery stenosis and refer for specialist assessment.</li></ul></li><li><strong>Managing serum potassium level</strong><ul><li>A rise of serum potassium level to up to 5.5 mmol/L is acceptable.</li><li>If elevated potassium levels persist, review concurrent medication that may increase potassium (including spironolactone, nonsteroidal anti-inflammatory drugs, and nephrotoxic drugs).</li><li>A rise of serum potassium to 5.5–6.0 mmol/L should prompt stopping the AIIRA and seeking specialist advice.</li><li>A rise of serum potassium to over 6.0 mmol/L should prompt stopping of all medications that may increase potassium (including the AIIRA) and seek urgent specialist advice.</li></ul></li><li><strong>Managing serum sodium</strong><ul><li>Seek specialist advice if serum sodium falls to under 132 mmol/L.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Smellie et al, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Smellie et al, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">London and South East Medicines Information Service et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>]</p><!-- end field 094780db-e6ba-4b81-a70b-d2cbf5dccf87 --><!-- end item 15bfad7f-afbf-4e13-89ff-63c3858eb5cf -->","subChapters":[]},{"id":"54f8006e-19cb-5ed5-82c2-384b1ec9dabb","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 5455877d-f001-48fb-856c-2e85a0324cef --><h3>Contraindications and cautions of AIIRAs</h3><!-- end field 5455877d-f001-48fb-856c-2e85a0324cef -->","summary":"","htmlStringContent":"<!-- begin item f6d7c95a-5cf6-4d51-b519-965ba8b5fb7f --><!-- begin field b08803e0-a87e-425a-b325-c3947bd0caa9 --><ul><li>Do not prescribe angiotensin-II receptor antagonists (AIIRAs) to people with:<ul><li>Hereditary or idiopathic angio-oedema or a history of angio-oedema associated with previous exposure to an AIIRA.</li><li>Bilateral renal artery stenosis or renal artery stenosis in a single functioning kidney.</li><li>Severe hepatic impairment, biliary cirrhosis and/or cholestasis.</li><li>Some AIIRA preparations contain lactulose and should not be used by people with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.</li><li>Chronic kidney disease (CKD) with a pre-treatment serum potassium concentration greater than 5.0 mmol/L.</li></ul></li><li>Use AIIRAs with caution in people with:<ul><li>Concurrently prescribed diuretics (especially more than 80 mg of furosemide daily or its equivalent). First doses can cause hypotension (especially in those taking high doses, on a low-sodium diet, on dialysis, or the presence of dehydration). For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-aiiras/#key-drug-interactions\">Drug interactions</a>.</li><li>Peripheral arterial disease or generalized atherosclerosis there is a risk of clinically silent renovascular disease.</li><li>Pre-existing renovascular disease (specialist initiation only).</li><li>CKD — monitor the response (hyperkalaemia is more common) and consider dose adjustment.</li><li>Severe or symptomatic aortic stenosis (risk of hypotension).</li><li>Mitral valve stenosis.</li><li>Hypertrophic cardiomyopathy.</li><li>Severe heart failure.</li><li>Hypovolaemia or hypotension (systolic pressure below 90 mmHg) or concurrent high-dose vasodilator therapy.</li><li>High pre-treatment serum potassium level (greater than 5 mmol/L).</li><li>Mild to moderate hepatic impairment.</li><li>Elderly people.</li><li>Afro-Caribbean people — especially those with left ventricular hypertrophy, who may not benefit.</li><li>Renal artery stenosis.</li><li>Primary aldosteronism — may not benefit.</li></ul></li><li>Consider the possibility of <a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/prescribing-information/managing-aiiras/#key-drug-interactions\">drug interactions of AIIRAs</a> with other medications.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">National Clinical Guidelines Centre, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">ABPI Medicines Compendium, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field b08803e0-a87e-425a-b325-c3947bd0caa9 --><!-- end item f6d7c95a-5cf6-4d51-b519-965ba8b5fb7f -->","subChapters":[]},{"id":"bc1c50d6-588c-5d44-9bc8-df7735e060e0","slug":"choice-of-aiiras","fullItemName":"Choice of AIIRAs","depth":3,"htmlHeader":"<!-- begin field 645f5f1d-e675-424b-97c1-2c6fd50fc176 --><h3>Choice of angiotensin-II receptor antagonist</h3><!-- end field 645f5f1d-e675-424b-97c1-2c6fd50fc176 -->","summary":"","htmlStringContent":"<!-- begin item f3822eed-2bb7-478a-b559-c1b0472a4596 --><!-- begin field 94f63632-8967-41ae-bcc7-5bd7f198ab44 --><p class=\"Bodytext\">Candesartan, losartan, and valsartan are licensed in the UK for the treatment of heart failure.</p><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>]</p><!-- end field 94f63632-8967-41ae-bcc7-5bd7f198ab44 --><!-- end item f3822eed-2bb7-478a-b559-c1b0472a4596 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}